Methods of lowering the error rate of massively parallel DNA sequencing using duplex consensus sequencing
View Patent ↗Next Generation DNA sequencing promises to revolutionize clinical medicine and basic research. However, while this technology has the capacity to generate hundreds of billions of nucleotides of DNA sequence in a single experiment, the error rate of approximately 1% results in hundreds of millions of sequencing mistakes. These scattered errors can be tolerated in some applications but become extremely problematic when “deep sequencing” genetically heterogeneous mixtures, such as tumors or mixed microbial populations. To overcome limitations in sequencing accuracy, a method Duplex Consensus Sequencing (DCS) is provided. This approach greatly reduces errors by independently tagging and sequencing each of the two strands of a DNA duplex. As the two strands are complementary, true mutations are found at the same position in both strands. In contrast, PCR or sequencing errors will result in errors in only one strand. This method uniquely capitalizes on the redundant information stored in double-stranded DNA, thus overcoming technical limitations of prior methods utilizing data from only one of the two strands.
1. A method of sequencing DNA comprising:
a) attaching partially single-stranded adapters comprising barcodes selected from a plurality of distinct barcode sequences to double-stranded DNA fragments obtained from a bodily sample, wherein attachment of the adapters to double-stranded DNA fragments generates a library of tagged double-stranded adapter-DNA molecules;
b) amplifying strands from a plurality of the double-stranded adapter-DNA molecules in the library to produce strand copies;
c) sequencing a plurality of the strand copies to obtain strand sequence reads comprising one or more barcode sequences and DNA fragment-specific information; and
d) for at least some of the double-stranded adapter-DNA molecules in the library—
grouping the strand sequence reads into families based on i) the barcode sequence, and ii) DNA fragment-specific information;
collapsing a plurality of strand sequence reads within the families to provide a consensus sequence for each of the at least some of the double-stranded adapter-DNA molecules in the library;
comparing the consensus sequence to a reference sequence;
analyzing one or more correspondences between the consensus sequence and the reference sequence to identify a sequence variation,
wherein the library comprises at least a subset of non-uniquely tagged double-stranded adapter-DNA molecules,
wherein non-uniquely tagged double-stranded adapter-DNA molecules are substantially identifiable with respect to other non-uniquely tagged double-stranded adapter-DNA molecules in the bodily sample using the one or more barcode sequences and DNA fragment-specific information,
wherein following step (d), the method further comprises identifying a genetic mutation conferring drug resistance present in one or more of the consensus sequences derived from the double-stranded DNA fragments obtained from a tumor cell population present in the bodily sample,
wherein the adapter comprises a hairpin loop with a uracil linker, and
wherein the barcode sequences are 6 nucleotides in length.
2. The method of claim 1 , wherein the bodily sample comprises tissue obtained from a subject.
3. The method of claim 1 , further comprising selectively enriching double-stranded adapter-DNA molecules or copies thereof to enrich for a subset of DNA molecules that map to one or more genetic loci in the reference sequence.
4. The method of claim 1 , wherein, prior to sequencing, double-stranded adapter-DNA molecules or copies thereof are selectively enriched using a hybridization capture method to provide target DNA molecules that map to one or more genetic loci in the reference sequence.
5. The method of claim 1 , wherein the plurality of distinct barcode sequences are a set of sequences known prior to sequencing.
6. The method of claim 1 , wherein prior to step (a), the method further comprises:
receiving a tissue sample from a human subject;
extracting DNA from the tissue sample; and
shearing the DNA to generate the plurality of double-stranded DNA fragments.
7. A method of sequencing DNA comprising:
a) attaching partially single-stranded adapters comprising barcodes selected from a plurality of distinct barcode sequences to double-stranded DNA fragments obtained from a bodily sample, wherein attachment of the adapters to double-stranded DNA fragments generates a library of tagged double-stranded adapter-DNA molecules;
b) amplifying strands from a plurality of the double-stranded adapter-DNA molecules in the library to produce strand copies;
c) sequencing a plurality of the strand copies to obtain strand sequence reads comprising one or more barcode sequences and DNA fragment-specific information; and
d) for at least some of the double-stranded adapter-DNA molecules in the library—
grouping the strand sequence reads based on i) the barcode sequence, ii) single-stranded portions of the adapters, and iii) DNA fragment-specific information;
collapsing a plurality of strand sequence reads within the groups to provide single strand consensus sequences; and
generating a consensus sequence by comparing single strand consensus sequences derived from the same double-stranded adapter-DNA molecules.
8. The method of claim 7 , wherein the library comprises at least a subset of non-uniquely tagged double-stranded adapter-DNA molecules.
9. The method of claim 8 , wherein non-uniquely tagged double-stranded adapter-DNA molecules are identifiable with respect to other non-uniquely tagged double-stranded adapter-DNA molecules in the bodily sample using the one or more barcode sequences and DNA fragment-specific information.
10. The method of claim 7 , wherein following step (d), the method further comprises identifying a genetic mutation conferring drug resistance present in one or more of the consensus sequences derived from the double-stranded DNA fragments obtained from a tumor cell population present in the bodily sample.
11. The method of claim 7 , wherein step (d) further comprises:
comparing the consensus sequence to a reference sequence; and
analyzing one or more correspondences between the consensus sequence and the reference sequence to identify a sequence variation.
12. The method of claim 11 , wherein the bodily sample is derived from a human subject and wherein the sequence variation is a drug-resistant variant derived from a tumor cell population in the human subject.
13. The method of claim 11 , wherein step (d) further comprises determining whether one or more cancer-associated sequence variations are present in the consensus sequence that is not present in the reference sequence.
14. The method of claim 13 , wherein—
the bodily sample is derived from a human subject; and
if a cancer-associated sequence variation is present, step (d) further comprises determining if the cancer-associated sequence variation is associated with one or more of (i) a drug-resistant variant of a cancer in the subject, or (ii) a cancer at an early stage in the subject, or (iii) a sequence variant in a genetically heterogeneous tumor within the subject, or (iv) a cancer risk in the subject.
15. The method of claim 11 , further comprising selectively enriching double-stranded adapter-DNA molecules or copies thereof to enrich for a subset of DNA molecules that map to one or more genetic loci in the reference sequence.
16. The method of claim 11 , wherein, prior to sequencing, double-stranded adapter-DNA molecules or copies thereof are selectively enriched using a hybridization capture method to provide target DNA molecules that map to one or more genetic loci in the reference sequence.
17. The method of claim 7 , wherein at least some of the adapters comprise a hairpin loop with a cleavable linker.
18. The method of claim 7 , wherein the library of tagged double-stranded adapter-DNA molecules comprise a plurality of tagged double-stranded adapter-DNA molecules having a Y-shape on one or both ends of the double-stranded adapter-DNA molecules.
19. The method of claim 7 , wherein the barcode sequences are 3, 4, 5, 6, 7 or 8 nucleotides in length.
20. The method of claim 7 , wherein the barcode sequences are between 3 and 20 nucleotides in length.
21. The method of claim 7 , wherein the plurality of distinct barcode sequences are a set of sequences known prior to sequencing.
22. The method of claim 7 , wherein the attaching comprises blunt-end ligation or sticky end ligation.
23. The method of claim 7 , wherein the bodily sample comprises double-stranded DNA fragments of a desired size.
24. The method of claim 7 , wherein prior to step (a), the method further comprises:
receiving the bodily sample from a human subject;
extracting DNA from the bodily sample; and
fragmenting the DNA to generate the plurality of double-stranded DNA fragments.
25. The method of claim 24 , wherein fragmenting the DNA comprises shearing the DNA to generate the plurality of double-stranded DNA fragments.
26. The method of claim 24 , wherein fragmenting the DNA comprises enzymatically cutting the DNA to generate the plurality of double-stranded DNA fragments.